Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.

Trial Details

NCT ID
NCT06300528
Phase
PHASE2
Sponsor
University of Utah
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Pemigatinib
Locations (sample)
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Subjects aged ≥ 18 years.
  • ECOG Performance Status ≤ 2.
  • Histologically confirmed MCL or MZL, including EMZL/MALT lymphoma, SMZL, and NMZL.
  • -Patients with gastric MALT lymphoma and those who are H. Pylori positive need to have failed a trial of H. Pylori eradication and are either ineli…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →